Dehydroepiandrosterone sulphate: diabolical hormone or epiphenomenon in aneurysmal subarachnoid hemorrhage?-Reference-Cited by-同舟云学术

Dehydroepiandrosterone sulphate: diabolical hormone or epiphenomenon in aneurysmal subarachnoid hemorrhage?

Published:2015-12 Issue:1 Volume:19 Page:
ISSN:1364-8535
Container-title:Critical Care
language:en
Short-container-title:Crit Care

Author:

Murthy Santosh B.,Naval Neeraj S.

Abstract

AbstractInflammation is purported to play an important role in the clinical course of subarachnoid hemorrhage. The current study by Höllig et al. entails using dehydroepiandrosterone sulfate, a hormone that inhibits key inflammatory pathways, as a predictor of functional outcome in these patients.

Publisher

Springer Science and Business Media LLC

Subject

Critical Care and Intensive Care Medicine

Link

https://link.springer.com/content/pdf/10.1186/s13054-015-1069-4.pdf

Reference12 articles.

1. Dhar R, Diringer M. Statins and anti-inflammatory therapies for subarachnoid hemorrhage. Curr Treat Options Neurol. 2012;14:164–74.

2. Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD, STASH Collaborators. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol. 2014;13:666–75.

3. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43:1463–9.

4. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2). Acta Neurochir Suppl. 2013;115:27–31.

5. van den Bergh WM, MASH Study Group, Algra A, Dorhout Mees SM, van Kooten F, Dirven CM, et al. Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study. Stroke. 2006;37:2326–30.